Perlegen Defunct: PGx Firm Shutters Doors After R&D Disappointments, Mounting Losses

January 13, 2010

A review of the privately held pharmacogenomics company's activities from when it opened its doors in 2000 to just before it shuttered in late 2009 suggests that despite partnerships with academia and big pharma, opportunistic R&D investments in key markets, and at least one recently launched commercial diagnostic product, the company was unable to remain solvent. R&D disappointments, losses related to a government contract, and the economic crisis may have directly forced the company to close.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.

In this issue of Pharmacogenomics Reporter

Video Spotlight

Sponsored Video: Ambry Genetics - "Fully-Automated"

RainDance's ThunderStorm System is a fully-automated and walkaway high-throughput targeted sequencing solution that enables researchers to process 96 samples per day run on a proven platform that generates higher-quality data faster than ever before.

February 07, 2012

Sponsored Video: Sage Science - Pippin DNA Size Selection

Sage Science is pleased to announce the introduction of the BluePippin DNA size selection system, a pulsed-field electrophoresis version of its popular Pippin Prep instrument.

January 31, 2012

ScienceOnline2012

Genome Technology's Tracy Vence interviewed Sandra Porter, president of Digital World Biology, and Kristi Holmes, a bioinformaticist at the Becker Medical Library, Washington University School of Medicine at ScienceOnline2012.

February 02, 2012

Highlights from SC11 Part IV

In this video, we speak with Todd Smith, senior leader of research and applications of PerkinElmer, and researchers from Stockholm University on accelerating the GROMACS molecular dynamics software suite with GPUs and CPUs.

January 13, 2012
Young Investigator Profile

Helge Grosshans

Friedrich Miescher Institute for Biomedical Research
Senior Group Leader

MicroRNA Mediation

The Grosshans lab is aiming to find out how miRNAs achieve repression of their target mRNAs and how miRNAs are made and regulated using C. elegans. In addition to exploiting its traditional strengths in genetics and cell biology, they are also developing and applying biochemical assays. So far, they have been able to identify an miRNA degradation pathway that prevents detrimental increases in mature miRNA levels and to recapitulate this process biochemically.
Blog

MicroRNA Signatures of Breast Cancer

Ohio State University's Carlo Croce and colleagues find a microRNA signature for breast cancer.

February 08, 2012

This Week in the Journal of Clinical Pathology

In the Journal of Clinical Pathology this week: comparison of FISH and MLPA to detect HER2 and Topo 2 amplifications, TLR-4 expression in aggressive follicular thyroid cancer, and more.

February 08, 2012

Let the Games Begin

More and more, researchers are using games to get help answering their questions.

February 08, 2012

Ancient DNA Online

Svante Pääbo and his colleagues have posted the Denisovan DNA sequence for all to use.

February 08, 2012
Papers of Note

Human Genetic Variation Alters Anthrax Toxin Sensitivity
Martchenko, Candille et al., PNAS
Researchers at Stanford University School of Medicine show that genetic variation affecting capillary morphogenesis gene 2, or CMG2, dramatically alters toxin sensitivity in humans. In its analysis, the team reports on "a CMG2 single-nucleotide polymorphism occurring frequently in African and European populations [that they found] independently altered toxin uptake." The group goes on to suggest "testing of genomically characterized human cell populations may offer a broadly useful strategy for elucidating effects of genetic variation on infectious disease susceptibility."

Genomic Epidemiology of the 2011 Escherichia coli O104:H4 Outbreaks
Grad, Lipsitch et al., PNAS
An international team led by investigators at Brigham and Women's Hospital in Boston reports on the genomic epidemiology of the 2011 Escherichia coli O104:H4 outbreaks in Europe, saying that the "striking difference in diversity between the German and French outbreak samples" it observed "is consistent with several hypotheses, including a bottleneck that purged diversity in the German isolates, variation in mutation rates in the two E. coli outbreak populations, or uneven distribution of diversity in the seed populations that led to each outbreak."
People on the Move

Life Technologies this week named Alan Sachs as head of global research and development and Ronnie Andrews as president of medical sciences.

Sachs was previously the vice president of exploratory and translational sciences for Merck Research Laboratories, where he spent 10 years in various leadership roles, Life Tech said. Prior to that Sachs served an associate professor of biochemistry and molecular biology at the University of California, Berkeley, and as a Whitehead fellow at the Whitehead Institute for Biomedical Research.

Andrews joins Life Tech from GE Molecular Diagnostics, where he served as a segment leader following GE's 2010 acquisition of Clarient, where Andrews was CEO. Andrews has also held executive positions with Abbott Diagnostics, Roche Diagnostics, and Immucor.

Stephen O'Brien has left the National Cancer Institute's Laboratory of Genomic Diversity after 25 years to help launch a genome bioinformatics program at St. Petersburg University in Russia. O'Brien received a $5 million grant from the Russian Ministry of Education and Science last year under a program that aims to lure big-name researchers to Russia. Over the coming three years, O'Brien will spend at least four months per year in Russia working at the center, which is scheduled to open in May.

Saladax Biomedical said today that President and CEO Edward Erickson has resigned due to personal and family reasons, and that he will be replaced by Kevin Harter on an interim basis. Erickson will remain a member of the company's board of directors. Harter is a co-founder and senior VP of the Life Sciences Greenhouse, and he has served as executive chairman at Saladax.
Upcoming Events

Conferences, Meetings & Deadlines

AGBT 2012
Feb 15-18 / Marco Island, Fla.
AGBT

Omics and Personalized Health
Feb 16-18 / Heidelberg, Germany
EMBL

AAAS Annual Meeting
Feb 16-20 / Vancouver, Canada
AAAS

Molecular Med Tri-Con 2012
Feb 19-23 / San Francisco
CHI

International Conference and Exhibition on Metabolomics & Systems Biology
Feb 20-22 / San Francisco
OMICS Publishing Group

Abstract & Registration Deadlines

more

Science
Members of the International Stroke Genetics Consortium and the Wellcome Trust Case Control Consortium 2 did a GWAS involving thousands of individuals of European descent with or without a history of stroke and found a new genetic variant that contributes to a form of stroke called large vessel ischemic stroke. The variant was found in in the histone deacetylase 9 coding gene HDAC9 on chromosome 7.
Business
PerkinElmer reported fourth-quarter revenue growth of 15 percent, or 6 percent organically, compared to Q4 2010 and beat analysts' estimates on the top and bottom line. The firm is in the process of integrating Caliper Life Sciences and a few bioinformatics companies, and company officials said there would be a pause in M&A activity for the next several months - though diagnostics remains a "significant priority."
Funding
Canada launched a new program that will pump C$67.5 million (US$67.3 million) into projects that will use genomics-based research to advance personalized healthcare. The 2012 Large-Scale Applied Research Project Competition in Genomics and Personalized Health is funded with C$40 million from Genome Canada, C$22.5 million from the Canadian Institute of Health Research, and C$5 million from the Cancer Stem Cell Consortium.
Genome Technology Magazine
With academic hiring having nearly come to a halt, life scientists increasingly find themselves searching for careers beyond the ivory tower. This month, GT presents a global snapshot of where the genomics jobs are outside of academia, and an insiders' look into how to land them.

Search

Perlegen Defunct: PGx Firm Shutters Doors After R&D Disappointments, Mounting Losses

Related Stories

In this issue of Pharmacogenomics Reporter

Video Spotlight

Young Investigator Profile

Blog

Papers of Note

People on the Move

Upcoming Events

Science

Business

Funding

Genome Technology Magazine

TechGuides Listings

Poll